Skip to main content

Articles

Page 1 of 3

  1. We have previously reported an increased risk for non-hematological malignancies in young patients with moderate or severe aortic stenosis (AS). These findings were the result of a post-hoc analysis from a lar...

    Authors: Walid Saliba, Tamir Bental, Yaron Shapira, Shmuel Schwartzenberg, Alex Sagie, Moti Vaturi, Salim Adawi, Alexander Fuks, Ami Aronheim and Avinoam Shiran

    Citation: Cardio-Oncology 2021 7:37

    Content type: Research

    Published on:

  2. Gilteritinib is a novel FMS-like tyrosine kinase 3 inhibitor recently approved by the United States Food and Drug Administration in 2018 for relapsed or refractory acute myeloid leukemia. However, gilteritinib...

    Authors: Lisa Kim, Brian Fowler, Courtney M. Campbell, Jeremy Slivnick, Haseeb Nawaz, Yaquta Kaka, Patrick Ruz, Ajay Vallakati, Ragavendra Baliga, Sumithira Vasu and Daniel Addison

    Citation: Cardio-Oncology 2021 7:36

    Content type: Case report

    Published on:

  3. Sacubitril/valsartan has been shown to significantly reduce cardiovascular mortality and hospitalizations due to heart failure in patients with reduced ejection fraction (HFrEF) when compared to enalapril. Dat...

    Authors: Maria Klara Frey, Henrike Arfsten, Noemi Pavo, Emilie Han, Stefan Kastl, Martin Hülsmann, Mariann Gyöngyösi and Jutta Bergler-Klein

    Citation: Cardio-Oncology 2021 7:35

    Content type: Research

    Published on:

  4. Significantly increased risks of cardiovascular disease occur in testicular cancer survivors given cisplatin-based chemotherapy. The postulated mechanism of platinum-based chemotherapy’s vascular toxicity has ...

    Authors: Suparna C. Clasen, Paul C. Dinh Jr, Lifang Hou, Chunkit Fung, Howard D. Sesso and Lois B. Travis

    Citation: Cardio-Oncology 2021 7:34

    Content type: Short communication

    Published on:

  5. Recent advances in the treatment algorithms of early breast cancer have markedly improved overall survival. However, anthracycline- and trastuzumab-associated cardiotoxicity may lead to dose-reduction or halt ...

    Authors: A Mecinaj, G Gulati, SL Heck, E Holte, MW Fagerland, AI Larsen, E.S Blix, J Geisler, T Wethal and T Omland

    Citation: Cardio-Oncology 2021 7:33

    Content type: Research

    Published on:

  6. Cardiotoxicity resulting in heart failure (HF) is among the most dreaded complications of cancer therapy and can significantly impact morbidity and mortality. Leading professional societies in cardiology and o...

    Authors: Anecita P. Fadol, Ashley Patel, Valerie Shelton, Kate J. Krause, Eduardo Bruera and Nicolas L. Palaskas

    Citation: Cardio-Oncology 2021 7:32

    Content type: Review

    Published on:

  7. Nilotinib, a second-generation BCR-ABL tyrosine kinase inhibitor (TKI), is highly effective in the treatment of patients with chronic myeloid leukemia (CML), despite being more vasculotoxic than older TKIs suc...

    Authors: Shunsuke Maruta, Kyohei Usami, Kazuko Tajiri, Masafumi Otani, Daigo Hiraya, Hiroaki Watabe, Tomoya Hoshi, Akira Sato and Masaki Ieda

    Citation: Cardio-Oncology 2021 7:31

    Content type: Case report

    Published on:

  8. While pre-existing cardiovascular disease (CVD) appears to be associated with poor outcomes in patients with Coronavirus Disease 2019 (COVID-19), data on patients with CVD and concomitant cancer is limited. Th...

    Authors: David M. Tehrani, Xiaoyan Wang, Asim M. Rafique, Salim S. Hayek, Joerg Herrmann, Tomas G. Neilan, Pooja Desai, Alicia Morgans, Juan Lopez-Mattei, Rushi V. Parikh and Eric H. Yang

    Citation: Cardio-Oncology 2021 7:28

    Content type: Research

    Published on:

  9. Immune checkpoint inhibitor (ICI) induced myocarditis is a rare, severe, and often fatal adverse event. Evidence to guide appropriate immunosuppressive therapy is scarce. We present a case of ICI-induced myoca...

    Authors: Emma Matzen, Lars Erik Bartels, Brian Løgstrup, Stine Horskær, Christina Stilling and Frede Donskov

    Citation: Cardio-Oncology 2021 7:27

    Content type: Review

    Published on:

  10. The emergence of immune checkpoint inhibitors (ICIs) has brought about a paradigm shift in cancer treatment as the use of these drugs has become more frequent and for a longer duration. As a result of T-cell-m...

    Authors: Shingo Kazama, Ryota Morimoto, Yuki Kimura, Naoki Shibata, Reina Ozaki, Takashi Araki, Takashi Mizutani, Hideo Oishi, Yoshihito Arao, Tasuku Kuwayama, Hiroaki Hiraiwa, Toru Kondo, Kenji Furusawa, Tomoya Shimokata, Takahiro Okumura, Yasuko K. Bando…

    Citation: Cardio-Oncology 2021 7:26

    Content type: Research

    Published on:

  11. Cardiovascular disease (CVD) and cancer are the top mortality causes globally, yet little is known about how the diagnosis of cancer affects treatment options in patients with hemodynamically compromising aort...

    Authors: Dominique J. Monlezun, Logan Hostetter, Prakash Balan, Nicolas Palaskas, Juan Lopez-Mattei, Mehmet Cilingiroglu, Zaza Iakobishvili, Michael Ewer, Konstantinos Marmagkiolis and Cezar Iliescu

    Citation: Cardio-Oncology 2021 7:25

    Content type: Research

    Published on:

  12. Increasing evidence suggests a multifaceted relationship exists between cancer and cardiovascular disease (CVD). Here, we introduce a 5-tier classification system to categorize cardio-oncology syndromes (COS) ...

    Authors: Rudolf A. de Boer, Joseph Pierre Aboumsallem, Valentina Bracun, Douglas Leedy, Richard Cheng, Sahishnu Patel, David Rayan, Svetlana Zaharova, Jennifer Rymer, Jennifer M. Kwan, Joshua Levenson, Claudio Ronco, Paaladinesh Thavendiranathan and Sherry-Ann Brown

    Citation: Cardio-Oncology 2021 7:24

    Content type: Review

    Published on:

  13. Cancer therapy-related cardiac dysfunction may occur in pediatric cancer survivors. Identification of early markers of myocardial damage secondary to anthracycline exposure is crucial to develop strategies tha...

    Authors: Cory V. Noel, Nino Rainusso, Matthew Robertson, Jonathan Romero, Prakash Masand, Cristian Coarfa and Robia Pautler

    Citation: Cardio-Oncology 2021 7:23

    Content type: Research

    Published on:

  14. Women with breast cancer (BCA) and cardiovascular disease (CVD) risk factors are at increased risk of developing cardiovascular complications when exposed to potentially cardiotoxic cancer therapy. The benefit...

    Authors: Michael G. Fradley, Mohammed Alomar, Marcus W. Kilpatrick, Bernadette Shields, Nhi Tran, Amey Best, Erika Bianco, Merna Armanious, R. Ashton Vautier, Kevin Kip, Theresa M. Beckie and Roohi Ismail-Khan

    Citation: Cardio-Oncology 2021 7:22

    Content type: Research

    Published on:

  15. Cardiac metastasis due to colon cancer is extraordinarily uncommon. Given the rarity of diagnosis, there is paucity of evidence and hence, no established guidelines for evaluation or clinical management strategy.

    Authors: Humaira Sarfraz, Abeer Arain, Mukul K. Divatia, Mary R. Schwartz and Kirk E. Heyne

    Citation: Cardio-Oncology 2021 7:21

    Content type: Case report

    Published on:

  16. Cancer treatment-related morbidity relevantly compromises health status in cancer survivors, and efforts to optimise health-related outcomes in this population are vital to maximising healthy survivorship. A p...

    Authors: Renske Altena, Laila Hubbert, Narsis A. Kiani, Yvonne Wengström, Jonas Bergh and Elham Hedayati

    Citation: Cardio-Oncology 2021 7:20

    Content type: Review

    Published on:

  17. Modern therapies in oncology have increased cancer survivorship, as well as the incidence of cardiovascular adverse events. While immune checkpoint inhibitors have shown significant clinical impact in several ...

    Authors: Jessica Castrillon Lal, Sherry-Ann Brown, Patrick Collier and Feixiong Cheng

    Citation: Cardio-Oncology 2021 7:19

    Content type: Research

    Published on:

  18. Cancer patients with a history of radiotherapy are at an increased risk of ischemic heart disease. Preclinical animal studies demonstrate markedly impaired acetylcholine (ACh)-mediated endothelium-dependent va...

    Authors: Heather R. Banister, Stephen T. Hammond, Shannon K. Parr, Shelbi L. Sutterfield, Vanessa-Rose G. Turpin, Scott Treinen, Martin J. Bell and Carl J. Ade

    Citation: Cardio-Oncology 2021 7:18

    Content type: Research

    Published on:

  19. The CBR3 V244M single nucleotide polymorphism has been linked to the risk of anthracycline-related cardiomyopathy in survivors of childhood cancer. There have been limited prospective studies examining the impact...

    Authors: Jennifer K. Lang, Badri Karthikeyan, Adolfo Quiñones-Lombraña, Rachael Hageman Blair, Amy P. Early, Ellis G. Levine, Umesh C. Sharma, Javier G. Blanco and Tracey O’Connor

    Citation: Cardio-Oncology 2021 7:17

    Content type: Research

    Published on:

  20. Approximately 20% of cancer survivors treated with chemotherapy experience worsening heart failure (HF) symptoms post-cancer treatment. While research has predominantly investigated the role of cardiotoxic tre...

    Authors: Kerryn W. Reding, Nathaniel S. O’Connell, Ralph B. D’Agostino Jr, William Hundley, Alexander R. Lucas, Amy C. Ladd, Jennifer H. Jordan, Emily M. Heiston, Yaorong Ge and W. Gregory Hundley

    Citation: Cardio-Oncology 2021 7:16

    Content type: Short communication

    Published on:

  21. Breast cancer is the most common female cancer worldwide. Effective therapies including doxorubicin and trastuzumab have improved survival, but are associated with a substantial risk of cardiovascular disease....

    Authors: Rebecca K. Hoffman, Bang-Jin Kim, Payal D. Shah, Joseph Carver, Bonnie Ky and Sandra Ryeom

    Citation: Cardio-Oncology 2021 7:15

    Content type: Research

    Published on:

  22. The pathophysiology of hypertension and cancer are intertwined. Hypertension has been associated with an increased likelihood of developing certain cancers and with higher cancer-related mortality. Moreover, v...

    Authors: Turab Mohammed, Meghana Singh, John G. Tiu and Agnes S. Kim

    Citation: Cardio-Oncology 2021 7:14

    Content type: Review

    Published on:

  23. Glucocorticoid treatment remains the cornerstone of therapy for immune checkpoint inhibitor (ICI) myocarditis, but data supporting the use of additional immunotherapy for steroid refractory cases remains limit...

    Authors: Robert S. Zhang, Allison Padegimas, Kathleen M. Murphy, Peter T. Evans, Carli J. Peters, Christopher M. Domenico, Mahesh K. Vidula, Paul J. Mather, Marisa Cevasco, Roger B. Cohen, Joseph R. Carver and Rupal P. O’Quinn

    Citation: Cardio-Oncology 2021 7:13

    Content type: Research

    Published on:

  24. Trastuzumab reduces risk of breast cancer recurrence but carries risk of cardiotoxicity that may be reversible upon treatment cessation and institution of left ventricular (LV) enhancement therapies (LVETx). W...

    Authors: Ren Jie Robert Yao, Jordan Gibson, Christine Simmons and Margot K. Davis

    Citation: Cardio-Oncology 2021 7:12

    Content type: Research

    Published on:

  25. Immune checkpoint inhibitors (ICIs) are a novel class of anticancer agents that have demonstrated clinical response for both solid and hematological malignancies. ICIs are associated with development of immune...

    Authors: Nida Waheed, Michael G. Fradley, David L. DeRemer, Ahmad Mahmoud, Chintan P. Shah, Taimour Y. Langaee, Gloria P. Lipori, Keith March, Carl J. Pepine, Rhonda M. Cooper-DeHoff, Yonghui Wu and Yan Gong

    Citation: Cardio-Oncology 2021 7:10

    Content type: Research

    Published on:

  26. Due to advances in care, most women diagnosed with breast cancer do not die from the disease itself. Instead, cardiovascular disease (CVD) remains the most frequent cause of death. Many breast cancer patients ...

    Authors: Lisa Prior, Hannah Featherstone, David O’Reilly, Killian Nugent, Marvin Lim, John McCaffrey, Michaela J Higgins and Catherine M. Kelly

    Citation: Cardio-Oncology 2021 7:8

    Content type: Research

    Published on:

  27. Adjuvant systemic breast cancer treatment improves disease specific outcomes, but also presents with cardiac toxicity. In this post-hoc exploratory analysis of the OptiTrain trial, the effects of exercise on c...

    Authors: Josefin Ansund, Sara Mijwel, Kate A. Bolam, Renske Altena, Yvonne Wengström, Eric Rullman and Helene Rundqvist

    Citation: Cardio-Oncology 2021 7:7

    Content type: Research

    Published on:

  28. Cardiovascular toxicity is a notorious complication of doxorubicin (DXR) therapy for diffuse large B-cell lymphoma (DLBCL). Although surveillance of well-known biological markers for cardiovascular disease (CV...

    Authors: Charlott Mörth, Amal Abu Sabaa, Eva Freyhult, Christina Christersson, Jamileh Hashemi, Nashmil Hashemi, Masood Kamali-Moghaddam, Daniel Molin, Martin Höglund, Anna Eriksson and Gunilla Enblad

    Citation: Cardio-Oncology 2021 7:6

    Content type: Research

    Published on:

  29. Craniospinal irradiation (CSI) is part of the treatment of central nervous system (CNS) tumors and is associated with cardiovascular disease in adults. Global myocardial strain analysis including longitudinal ...

    Authors: Hugo R. Martinez, Ralph Salloum, Erin Wright, Lauren Bueche, Philip R. Khoury, Justin T. Tretter and Thomas D. Ryan

    Citation: Cardio-Oncology 2021 7:5

    Content type: Research

    Published on:

  30. Cancer therapy-related cardiac dysfunction (CTRD) is a major source of morbidity and mortality in long-term cancer survivors. Decreased GLS predicts decreased left ventricular ejection fraction (LVEF) in patie...

    Authors: Raquel Araujo-Gutierrez, Kalyan R. Chitturi, Jiaqiong Xu, Yuanchen Wang, Elizabeth Kinder, Alpana Senapati, L. Bindu Chebrolu, Mahwash Kassi and Barry H. Trachtenberg

    Citation: Cardio-Oncology 2021 7:4

    Content type: Research

    Published on:

  31. Cardiotoxicity remains a dreaded complication for patients undergoing chemotherapy with human epidermal growth factor (HER)-2 receptor antagonists and anthracyclines. Though many studies have looked at racial ...

    Authors: Crystal B. Chen, Raj K. Dalsania and Eman A. Hamad

    Citation: Cardio-Oncology 2021 7:3

    Content type: Research

    Published on:

  32. As cardiovascular disease is a leading cause of death in cancer survivors, the new subspecialty of Cardio-Oncology has emerged to address prevention, monitoring, and management of cardiovascular toxicities to ...

    Authors: Sherry-Ann Brown, Sahishnu Patel, David Rayan, Svetlana Zaharova, Mingqian Lin, Tarek Nafee, Bipin Sunkara, Ragasnehith Maddula, James MacLeod, Krishna Doshi, Joshua Meskin, David Marks and Jorge Saucedo

    Citation: Cardio-Oncology 2021 7:2

    Content type: Research

    Published on:

  33. Anti-neoplastic drugs have made major advancements in oncology, however they are not without cardiovascular consequences. We present a patient with cutaneous T-cell lymphoma receiving Targretin therapy who pre...

    Authors: Sean DeAngelo, Kailyn I. Mann, Muhammad Abdulbasit, Amy Ahnert and Deborah W. Sundlöf

    Citation: Cardio-Oncology 2020 6:31

    Content type: Short communication

    Published on:

  34. Takotsubo syndrome (TTS), also known as stress cardiomyopathy, apical ballooning syndrome and broken heart syndrome, is characterized by acute-onset chest pain, electrocardiographic (ECG) abnormalities and rev...

    Authors: Aline Cristini Vieira, Mauricio Fernando Silva Almeida Ribeiro, Julianne Lima, Jacob Sessim Filho, Heloisa de Andrade Carvalho and Max Senna Mano

    Citation: Cardio-Oncology 2020 6:30

    Content type: Short communication

    Published on:

  35. Iron deficiency (ID) and anemia are common in both heart failure (HF) and cancer patients and are associated with poor quality of life and survival. The aims of this study were (1) to evaluate the prevalence, ...

    Authors: E. Čiburienė, J. Čelutkienė, S. Aidietienė, G. Ščerbickaitė and A. R. Lyon

    Citation: Cardio-Oncology 2020 6:29

    Content type: Research

    Published on:

  36. Re-allocation of resources during the COVID-19 pandemic has resulted in delays in care delivery to patients with cardiovascular disease and cancer. The ability of health care providers to provide optimal care ...

    Authors: Diego Sadler, Jeanne M. DeCara, Joerg Herrmann, Anita Arnold, Arjun K. Ghosh, Husam Abdel-Qadir, Eric H. Yang, Sebastian Szmit, Nausheen Akhter, Monika Leja, Carolina Maria Pinto Domingues Carvalho Silva, Jayant Raikhelkar, Sherry-Ann Brown, Susan Dent, Rupal O’Quinn, Franck Thuny…

    Citation: Cardio-Oncology 2020 6:28

    Content type: Research

    Published on:

  37. Breast cancer survivors have double the risk of mortality from cardiovascular disease than age-matched women without a cancer history. Reynolds risk score (RRS) is a validated algorithm for the assessment of c...

    Authors: Kyuwan Lee, Nathalie Sami, Debu Tripathy, Wendy Demark-Wahnefried, Mary K. Norris, Kerry S. Courneya and Christina M. Dieli-Conwright

    Citation: Cardio-Oncology 2020 6:27

    Content type: Short communication

    Published on:

  38. Trastuzumab-induced cardiotoxicity (TIC) can lead to early discontinuation of adjuvant therapy, however there is limited evidence on long-term survival outcomes in patients with operable human epidermal growth...

    Authors: Sagar Sardesai, Jasmine Sukumar, Mahmoud Kassem, Marilly Palettas, Julie Stephens, Evan Morgan, Daniel Addison, Ragavendra Baliga, Daniel G. Stover, Jeffrey VanDeusen, Nicole Williams, Mathew Cherian, Maryam Lustberg, Robert Wesolowski and Bhuvaneswari Ramaswamy

    Citation: Cardio-Oncology 2020 6:26

    Content type: Research

    Published on:

  39. Sacubitril/Valsartan (S/V) is a novel and remarkably effective opportunity to treat heart failure with reduced ejection fraction (HFrEF). However, patients with HFrEF induced by cancer therapy were a priori ex...

    Authors: Massimiliano Camilli, Marco Giuseppe Del Buono, Pierantonio Menna and Giorgio Minotti

    Citation: Cardio-Oncology 2020 6:25

    Content type: Short communication

    Published on:

    The original article was published in Cardio-Oncology 2020 6:24

  40. Cancer therapy-related cardiac dysfunction (CTRCD) is a critical problem with an impact on both oncological and cardiovascular prognosis, especially when it prevents patients from receiving cancer treatment. S...

    Authors: Vanesa Gregorietti, Teresa Lopez Fernandez, Diego Costa, Elías Ortega Chahla and Andrés J. Daniele

    Citation: Cardio-Oncology 2020 6:24

    Content type: Research

    Published on:

    The Short communication to this article has been published in Cardio-Oncology 2020 6:25

  41. Anthracycline-induced cardiac dysfunction (ACD) is a notorious side effect of anticancer treatment. It has been described as a phenomenon of a continuous progressive decline of cardiac function, eventually lea...

    Authors: Janine A. M. Kamphuis, Marijke Linschoten, Maarten J. Cramer, Pieter A. Doevendans, Folkert W. Asselbergs and Arco J. Teske

    Citation: Cardio-Oncology 2020 6:23

    Content type: Research

    Published on:

  42. Immune checkpoint inhibition is part of standard systemic management for many advanced malignancies. Toxicities from this treatment approach are unpredictable, though usually reversible with management per est...

    Authors: Puja Arora, Laura Talamo, Patrick Dillon, Ryan D. Gentzler, Trish Millard, Michael Salerno, Craig L. Slingluff Jr and Elizabeth M. Gaughan

    Citation: Cardio-Oncology 2020 6:21

    Content type: Research

    Published on:

  43. An innovative Cardio-Oncology meeting was held in Houston, Texas in January of 2020. This gathering was intended to broaden the scope of Cardio-Oncology to include major presentations by clinicians and researc...

    Authors: Anecita P. Fadol, Nicolas L. Palaskas, Michael S. Ewer and Anita Deswal

    Citation: Cardio-Oncology 2020 6:20

    Content type: Review

    Published on:

  44. Consideration of heart health for cancer survivors is increasingly important, as improved cancer survivorship has resulted in a growing number of survivors affected by cardiovascular disease. However, there is...

    Authors: Claire C. Conley, Neha G. Goyal and Sherry-Ann Brown

    Citation: Cardio-Oncology 2020 6:19

    Content type: Short communication

    Published on:

Annual Journal Metrics

  • Speed
    37 days to first decision for reviewed manuscripts only
    34 days to first decision for all manuscripts
    74 days from submission to acceptance
    17 days from acceptance to publication

    Usage 
    68,327 Downloads
    280 Altmetric Mentions

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here